Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 120, Issue 10, 2013, Pages 1183-1191

  Myatt, L ^a   Clifton, R G ^b   Roberts, J M ^c   Spong, C Y ^d   Wapner, R J ^e   Thorp Jr , J M ^f   Mercer, B M ^g   Peaceman, A M ^h   Ramin, S M ⁱ   Carpenter, M W ^j   Sciscione, A ^k   Tolosa, J E ^l   Saade, G ^m   Sorokin, Y ⁿ   Anderson, G D ^m  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g METROHEALTH MEDICAL CENTER   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j BROWN UNIVERSITY   (United States)

^k CHRISTIANA CARE HEALTH SYSTEM   (United States)

^l OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^m UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

ⁿ WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Angiogenesis; endoglin; platelet growth factor; pre eclampsia; sFlt 1

Indexed keywords

ENDOGLIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MATERNAL PLASMA; MULTICENTER STUDY; PREECLAMPSIA; PRIORITY JOURNAL; RACE; SECOND TRIMESTER PREGNANCY; SENSITIVITY AND SPECIFICITY; UNITED STATES;

ANGIOGENESIS; ENDOGLIN; PLATELET GROWTH FACTOR; PRE-ECLAMPSIA; SFLT-1;

ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY MASS INDEX; EARLY DIAGNOSIS; FEMALE; HUMANS; LONGITUDINAL STUDIES; PARITY; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; RECEPTORS, CELL SURFACE; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84882236902     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.12128     Document Type: Article

References (21)

1. World Health Organization. Estimates of maternal mortality: a new approach by WHO and UNICED. Geneva, Switzerland: World Health Organization, 1996.
2. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995; 345: 1455-63.
3. Roberts JM, Hubel CA,. The two stage model of preeclampsia: variations on the theme. Placenta 2009; 30 (Suppl A): S32-7.
4. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005.
5. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21: 9-23.
6. Laigaard J, Sorensen T, Placing S, Holck P, Frohlich C, Wojdemann KR, et al. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol 2005; 106: 144-9.
7. Poon LC, Akolekar R, Lachmann R, Beta J, Nicoaides KH,. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol 2010; 35: 662-70.
8. Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007; 197: 35-e1.
9. Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW, et al. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 2012; 119: 1234-42.
10. Giguere Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem 2010; 56: 361-75.
11. Erez O, Romero R, Espinoza J, Fu W, Toden D, Kusanovic JP, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21: 279-87.
12. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998; 338: 701-5.
13. Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 2010; 362: 1282-91.
14. Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, Battisti M, et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 1997; 76: 517-31.
15. Clark DE, Smith SK, Licence D, Evans AL, Charnock-Jones DS,. Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J Endocrinol 1998; 159: 459-67.
16. Khaliq A, Li XF, Shams M, Sisi P, Acevedo CA, Whittle MJ, et al. Localisation of placenta growth factor (PIGF) in human term placenta. Growth Factors 1996; 13: 243-50,color plates I-II,pre bk cov.
17. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS,. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184: 1267-72.
18. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-58.
19. Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PE, Staff AC,. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007; 196: 239-e1.
20. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal B, Vaisbuch E, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009; 22: 1021-38.
21. Myatt L, Carpenter L,. Prediction of Preeclampsia. In:, Lyall F, Belfort M, editors. Preeclampsia Etiology and Clinincal Practice. Cambridge: Cambridge University Press; 2007. pp. 215-31.